BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

...the company would likely do so in the U.S.New investors in the B round included Vivo Capital...
...Emerge and Sunstone Life Science Ventures also participated.Priyanka Belawat of HBM Partners, Jack Nielsen of Vivo Capital...
...Other) IO102 IO103 Keytruda, pembrolizumab (MK-3475, lambrolizumab) IO Biotech ApS HBM Healthcare Investments University of Copenhagen Novo Seeds Bristol Myers Squibb Co. Novo Holdings A/S Vivo Capital Kurma...
BioCentury | Jan 12, 2021
Finance

Jan. 11 Quick Takes: Megarounds for Valo, Visen; plus NuProbe, Sensei

...and CDG Capital. All of the company’s existing investors participated, including Ascendis Pharma A/S (NASDAQ:ASND), Vivo Capital...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...first close of a $53.5 million series B+ round led by RA Capital Management and Vivo Capital...
...N.V. Boxer Capital EcoR1 Capital Omega Funds Vida Ventures Surveyor Capital Invus Wellington Management OrbiMed Casdin Capital Woodline Partners Logos Capital Janus Henderson Investors Atlas Venture Abingworth Kira Pharmaceuticals RA Capital Management Vivo Capital Foresite...
BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

...in Terns’ round included OrbiMed, Lilly Asia Ventures, Vivo Capital...
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...Asset Management; fellow new investors Boxer Capital of Tavistock Group, Janus Henderson, Samsara Biocapital and Vivo Capital...
BioCentury | Nov 10, 2020
Finance

RemeGen’s value surpasses $4B after pricing 2020’s largest biotech IPO

...in April, was led by Lilly Asia Ventures and Lake Bleu Capital. The company’s investors include Vivo Capital...
BioCentury | Oct 29, 2020
Finance

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix

...C round led by Wellington Management Co., OrbiMed Advisors and Morningside Ventures and new investor Vivo Capital...
BioCentury | Oct 2, 2020
Finance

Next stop IPO? Olema adds to momentum with $85M series C

...president and CEO, Olema has raised $85 million in a series C round led by Vivo Capital...
BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...develop rare disease therapies for patients in China. Founding investors Eight Roads, F-Prime Capital and Vivo Capital...
...BioCapital, Foresight Capital, Sphera, Fairmount and Soleus Capital. Existing investors OrbiMed Advisors, New Enterprise Associates, Vivo Capital...
BioCentury | Jul 10, 2020
Finance

$30M series A will propel Tranquis to the clinic with its neuroinflammation candidate

...clinic next year. Remiges Ventures and SR One co-led the tranched round, with participation from Vivo Capital...
Items per page:
1 - 10 of 170
BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

...the company would likely do so in the U.S.New investors in the B round included Vivo Capital...
...Emerge and Sunstone Life Science Ventures also participated.Priyanka Belawat of HBM Partners, Jack Nielsen of Vivo Capital...
...Other) IO102 IO103 Keytruda, pembrolizumab (MK-3475, lambrolizumab) IO Biotech ApS HBM Healthcare Investments University of Copenhagen Novo Seeds Bristol Myers Squibb Co. Novo Holdings A/S Vivo Capital Kurma...
BioCentury | Jan 12, 2021
Finance

Jan. 11 Quick Takes: Megarounds for Valo, Visen; plus NuProbe, Sensei

...and CDG Capital. All of the company’s existing investors participated, including Ascendis Pharma A/S (NASDAQ:ASND), Vivo Capital...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...first close of a $53.5 million series B+ round led by RA Capital Management and Vivo Capital...
...N.V. Boxer Capital EcoR1 Capital Omega Funds Vida Ventures Surveyor Capital Invus Wellington Management OrbiMed Casdin Capital Woodline Partners Logos Capital Janus Henderson Investors Atlas Venture Abingworth Kira Pharmaceuticals RA Capital Management Vivo Capital Foresite...
BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

...in Terns’ round included OrbiMed, Lilly Asia Ventures, Vivo Capital...
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...Asset Management; fellow new investors Boxer Capital of Tavistock Group, Janus Henderson, Samsara Biocapital and Vivo Capital...
BioCentury | Nov 10, 2020
Finance

RemeGen’s value surpasses $4B after pricing 2020’s largest biotech IPO

...in April, was led by Lilly Asia Ventures and Lake Bleu Capital. The company’s investors include Vivo Capital...
BioCentury | Oct 29, 2020
Finance

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix

...C round led by Wellington Management Co., OrbiMed Advisors and Morningside Ventures and new investor Vivo Capital...
BioCentury | Oct 2, 2020
Finance

Next stop IPO? Olema adds to momentum with $85M series C

...president and CEO, Olema has raised $85 million in a series C round led by Vivo Capital...
BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...develop rare disease therapies for patients in China. Founding investors Eight Roads, F-Prime Capital and Vivo Capital...
...BioCapital, Foresight Capital, Sphera, Fairmount and Soleus Capital. Existing investors OrbiMed Advisors, New Enterprise Associates, Vivo Capital...
BioCentury | Jul 10, 2020
Finance

$30M series A will propel Tranquis to the clinic with its neuroinflammation candidate

...clinic next year. Remiges Ventures and SR One co-led the tranched round, with participation from Vivo Capital...
Items per page:
1 - 10 of 170